S
Samuel Broder
Researcher at National Institutes of Health
Publications - 239
Citations - 28010
Samuel Broder is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Virus & Zidovudine. The author has an hindex of 82, co-authored 239 publications receiving 27794 citations. Previous affiliations of Samuel Broder include University of Miami & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Hiroaki Mitsuya,Kent J. Weinhold,P A Furman,M H St Clair,S N Lehrman,Robert C. Gallo,Dani P. Bolognesi,David Walter Barry,Samuel Broder +8 more
TL;DR: The antiviral effects of a thymidine analogue,3'-azido-3'-deoxythymidine (BW A509U), which, as a triphosphate, inhibits the reverse transcriptase of HTLV-III/LAV, and the in vitro immune functions of normal T cells remain basically intact.
Journal ArticleDOI
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
P A Furman,J A Fyfe,M H St Clair,Kent J. Weinhold,Rideout Janet L,G A Freeman,S N Lehrman,Dani P. Bolognesi,Samuel Broder,Hiroaki Mitsuya +9 more
TL;DR: The results reported here suggest that azidothymidine is nonselectively phosphorylated but that the triphosphate derivative efficiently and selectively binds to the HIV reverse transcriptase.
Journal Article
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.
Journal ArticleDOI
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
Hiroaki Mitsuya,Samuel Broder +1 more
TL;DR: In this paper, the capacity of purine and pyrimidine nucleoside derivatives to inhibit the infectivity and cytopathic effect of human T-lymphotropic virus type III in vitro was tested.
Journal ArticleDOI
Designing CD4 immunoadhesins for AIDS therapy
Daniel J. Capon,Steven M. Chamow,Joyce Mordenti,Scot A. Marsters,Timothy J. Gregory,Hiroaki Mitsuya,Randal A. Byrn,Catherine Lucas,Florian M. Wurm,Jerome E. Groopman,Samuel Broder,Douglas H. Smith +11 more
TL;DR: A newly-constructed antibody-like molecule containing the gp!20-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes, making it a good candidate for therapeutic use.